Complement: taking on Apellis with a gene therapy for geographic atrophy

Complement Therapeutics is leveraging the natural function of an endogenous complement inhibitor to develop a gene therapy to treat geographic atrophy. The biotech’s €72 million series A round co-led by Forbion and new investor Gimv, announced Monday, will bring it through clinical proof of concept. 

Complement Therapeutics GmbH spun out of University of Manchester in 2021 based on the work of three scientific founders: Simon Clark, a professor of AMD at the University of Tübingen; Paul Bishop, professor in ophthalmology at University of Manchester; and Richard Unwin, a researcher at Manchester. ...